Holmgren Calla, Aagaard-Tillery Kjersti M, Silver Robert M, Porter T Flint, Varner Michael
Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
Am J Obstet Gynecol. 2008 Jan;198(1):56.e1-4. doi: 10.1016/j.ajog.2007.06.004.
The objective of the study was to evaluate the use of interventions such as a peripherally inserted central catheters (PICC) line or nasogastric (NG)/nasoduodenal (ND) tube with the use of medications alone in the management of pregnancies with hyperemesis.
Subjects were identified with confirmed intrauterine pregnancy, admitted with hyperemesis gravidarum (HEG) between 1998 and 2004. Medical records were then abstracted for information with regard to therapy. Subjects were assigned on the basis of the management plan: medication alone, PICC line, or NG/ND tube. Outcomes were compared between groups.
Ninety-four patients met study criteria and had complete outcome data available. Of those, 33 had a PICC line placed (35.1%), 19 had a NG/ND placed (20.2%), and 42 were managed with medication alone (44.7%). These groups were similar with respect to gestational age at delivery, Apgar score, and mean birthweight. Maternal complications were significantly higher among those with PICC lines. Of patients managed with PICC lines, 66.4% (P < .001) required treatment for infection, thromboembolism, or both. Adjusted odds ratio for a PICC line complication was 34.5 (5.09, 233.73).
Maternal complications associated with PICC line placement are substantial despite no difference in neonatal outcomes, suggesting that the use of PICC lines for treatment of HEG patients should not be routinely used.
本研究的目的是评估在外周静脉穿刺中心静脉导管(PICC)置管或鼻胃管(NG)/鼻十二指肠管(ND)置管等干预措施联合单纯药物治疗在妊娠剧吐管理中的应用。
纳入1998年至2004年间确诊为宫内妊娠并因妊娠剧吐(HEG)入院的患者。然后提取病历以获取有关治疗的信息。根据管理计划将患者分组:单纯药物治疗、PICC置管或NG/ND置管。比较各组间的结局。
94例患者符合研究标准并可获得完整的结局数据。其中,33例放置了PICC(35.1%),19例放置了NG/ND(20.2%),42例仅接受药物治疗(44.7%)。这些组在分娩时的孕周、阿氏评分和平均出生体重方面相似。PICC置管患者的母体并发症显著更高。在接受PICC置管的患者中,66.4%(P < .001)需要接受感染、血栓栓塞或两者的治疗。PICC置管并发症的校正比值比为34.5(5.09,233.73)。
尽管新生儿结局无差异,但与PICC置管相关的母体并发症严重,这表明不应常规使用PICC置管治疗HEG患者。